Introduction
Aspiration of gastric contents in anesthetic practice is associated with a high mortality and morbidity especially during emergency procedures.
[1] A gastric pH < 2.5 and a volume >25 mL is critical to the pulmonary damage in adult patients [2] but low volume pulmonary aspirates (0.3 mL/kg) with pH less than one have resulted in high (90%) mortality rates in rats.
[3] H 2 -antagonists, antacids and drugs that modify gastric emptying have been used to reduce pulmonary injury that follows aspiration of gastric contents.
[4] H 2 antagonists [5, 6] are the preferred preanaesthetic for prevention of acid aspiration syndrome. Neuromuscular blocking drugs, which promote skeletal muscle relaxation, are administered routinely for tracheal intubation, during major surgical as well as minor procedures like scopies. However, there is a potential for interaction with neuromuscular blockers. Omeprazole [7] and cimetidine [8] have been reported to enhance the action of neuromuscular blockers. Cimetidine has been shown to prolong the duration of action of vecuronium.
[8] At high concentration, nizatidine and ranitidine potentiated the neuromuscular blocking activity of d-tubocurarine, while a reverse action was noted at lower concentration. [9] Famotidine did not alter the neuromuscular blockade produced by vecuronium. [10] Roxatidine, by itself caused blockade of neuromuscular transmission apart from potentiating the neuromuscular blockade induced by d-tubocurarine, pancuronium and aminoglycoside-kanamycin. [11] In view of the diverse reports, the present study was planned to examine the interaction of 
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H 2 antagonists famotidine and roxatidine acetate with the long acting neuromuscular blocker, pipecuronium, using the sciatic-gastrocnemius nerve-muscle preparation of rat in vivo.
Materials and Methods

Drugs
Benzyl alcohol (Sarabhai Chemicals, Baroda); famotidine (Intas Pharmaceuticals Ltd., Ahmedabad); pipecuronium (Themis Pharmaceuticals, Mumbai); roxatidine acetate hydrochloride (Hoechst India Limited, Mumbai). Benzyl alcohol (vehicle of famotidine) was diluted in saline and equivalent of blockade were studied: dilution was prepared as per its concentration present in stock Results solution of famotidine injection (i.e., 0.9 % v/v of benzyl alcohol in 10 mg/mL of famotidine injection). Contents of the Effects of pipecuronium, famotidine and roxatidine acetate ampoules of famotidine (10 mg/mL) and pipecuronium on the basal contractile twitch response of sciatic nerve (2 mg/mL) were diluted in saline and roxatidine acetate stimulated gastrocnemius preparation powder was dissolved in saline. Appropriate fresh saline Pipecuronium produced a dose-dependent inhibition of the dilutions of all the drugs were prepared on the day of the nerve stimulated basal contractile twitch responses of the experiment. All the drugs/vehicle (including pipecuronium) muscle. Both the vehicle (benzyl alcohol) and famotidine did intravenously, 30 min prior to not produce any significant effect on the preparation (data not shown). Roxatidine acetate (0.2 and 0.5 mg/kg) significantly Albino rats (250-400 gm) of either sex were fasted for inhibited the basal twitch response (i.e., 16.63 ± 1.84% and 24 hour prior to the experiment. Under urethane (1.25 g/kg 20.23 ± 4.43%, respectively). The ID ip) tracheotomy was done and artificially ventilated (8-10 mL/ of pipecuronium produced a 51% of inhibition of the nerve kg volume of air with 50-70 strokes per minute) using, rodent stimulated contractile twitch responses. Effects of famotidine respiratory pump. The external jugular vein was cannulated and roxatidine acetate on neuromuscular blockade produced for drug administration. The gastrocnemius-sciatic muscleby ID 50 (26.89 µg/kg) dose of pipecuronium nerve preparation was set up as described by Mishra et al. [12] Pretreatment with either vehicle or lower dose (0.5 mg/ The body temperature was maintained using homoeothermic kg) of famotidine did not modify the blockade produced by surgical table and overhead lamp. The preparation was allowed pipecuronium or its ID 50 value [ Table 1 ]. However, intermediate to stabilize for 30 min before starting the experiment. With dose (2 mg/kg) produced leftward shift of the dose response the student's physiograph, (Bio Device, Ambala) the sciatic curve of pipecuronium with a significant decrease in ID nerve was stimulated (2V, 0.1 Hz and 0.2 ms) using a bipolar while higher dose (5 mg/kg) produced an opposite effect electrode (Dastre's electrode) stimulator and the baseline [ Table 1 ]. contractile twitch responses were recorded. Pipecuronium Roxatidine acetate in lower dose (0.05 mg/kg) did not 1 0 µg/kg was administered i.v. every 30 sec till complete significantly modify the neuromuscular blockade induced by paralysis (i.e., till complete inhibition of the basal contractile pipecuronium or its ID 50 value [ Table 1 ]. However, intermediate twitch response). Dose required to produce 50% paralysis (ID 50 dose (0.2 mg/kg) of roxatidine acetate produced parallel value) was calculated by the best fitting regression line.
rightward shift of the dose response curve of pipecuronium Effects of highest doses (0.4 mL of benzyl alcohol 0.9% with a significant increase in the ID v/v (vehicle for famotidine), famotidine (0.5, 2 and 5 mg/kg) (0.5 mg/kg) produced a parallel leftward shift of dose response and roxatidine acetate (0.05, 0.2 and 0.5 mg/kg) were studied curve with a significant decrease in the ID 50 [ Table 1 ]. in the nerve-muscle preparation using separate group of six Effects of famotidine and roxatidine acetate on different animals each. For each drug, the effect of a single dose was parameters of neuromuscular blockade produced by the ID 50 studied for 3 min. The following parameters of neuromuscular (26.89 µg/kg) dose of pipecuronium Famotidine has been reported to potentiate the higher dose (5 mg/kg) significantly increased the time neuromuscular blockade produced by d-tubocurarine, required for onset of neuromuscular blockade produced by pancuronium and aminoglycoside antibiotics. [11] dose of pipecuronium without modifying the time potentiation of could be either (i) due to antagonism of calcium required for the peak effect and recovery from the blockade ions at presynaptic site as reported for the H cimetidine and ranitidine [10] Roxatidine acetate (0.05 and 0.2 mg/kg) significantly blocking effect. [11] increased the time required for the onset of neuromuscular Higher dose (5 mg/kg) of famotidine significantly blockade and at 0.2 and 0.5 mg/kg doses significantly antagonized pipecuronium-induced paralysis (increase in increased the time required for the development of peak ID 50 ; rightward shift) with significant increase in the time blockade produced by ID 50 dose of pipecuronium (26.89 µg/ required for onset of paralysis without modifying the time kg). Roxatidine acetate (0.5 mg/kg) significantly increased the required for peak effect and recovery from the paralysis. The time required for the peak effect and recovery from the antagonism by famotidine may be attributed to its weak neuromuscular blockade produced by ID 50 dose of pipecuronium anticholinesterase activity, [15] [ Table 3 ]. vivo. [16, 17] Thus it is likely that the rightward shift of dose Discussion response curve of pipecuronium could be due to delay in onset of paralysis produced by famotidine. These results are Pipecuronium (50 mg/kg) produced complete blockade in contrast to those reported by Mishra et al [10] of the twitch responses of the sciatic nerve stimulated atracurium and gallamine whereas, we employed gastrocnemius preparation, which is in line with previous pipecuronium; therefore discrepancies could be attributed experimental [12] and clinical studies. [13] Benzyl alcohol (vehicle) to difference in the neuromuscular blocker employed. did not modify any of the parameters studied. Mishra et al [14] Roxatidine acetate, a new H reported that famotidine failed to alter the steady state profound inhibition of gastric secretion [18] appears to reduce paralysis produced by non-depolarising (e.g., atracurium and the risk of aspiration pneumonitis by decreasing the volume gallamine) as well as depolarising (e.g., succinylcholine) and increasing the pH. [19] In the present study, lower dose blockers in vivo in rats. Similar results were obtained with low (0.05 mg/kg) did not produce any change in the contractile dose (0.5 mg/kg) famotidine in the present study involving twitch response while intermediate (0.2 mg/kg) and higher 
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dose (0.5 mg/kg) produced significant paralysis, which reached to steady state in 30 min. Bossa et al [11] reported similar observations; however, they used very high dose of roxatidine acetate (i.e. 40 and 80 mg/kg i.v.) in the preparation stimulated at high (3 Hz) frequency. In the present study, we used very low doses (i.e., 0.2 mg/kg and 0.5 mg/kg) of roxatidine acetate in the preparation stimulated at low (0.5 Hz) frequency, which may be relevant to the clinical situation. The mechanism by which roxatidine acetate significantly reduced the contractile twitch responses could be ascribed to an action at presynaptic level, mediated by decrease in calcium influx. [11] by roxatidine acetate at neuromuscular junction could be due to desensitization of nicotinic receptor as reported for some drugs.
[23] However, further work is required to delineate the exact mechanism of potentiation of pipecuronium-induced paralysis by higher dose of roxatidine acetate.
Conclusion
It is concluded that since famotidine per se had no effect on twitch responses and had produced less pharmacodynamic drug interaction as compared to roxatidine acetate with pipecuronium, it may be preferred as pre medication agent in clinical practice. Besides roxatidine acetate Lower dose (0.05 mg/kg), of roxatidine acetate did not blocked, the twitch responses of the gastrocnemius sciatic alter pipecuronium-induced paralysis (ID 50 value), while it nerve preparation suggesting caution in its use especially in significantly increased the time required for the onset of patients receiving drugs that depresses neuromuscular paralysis without modifying the time required for to develop transmission e.g., aminoglycoside antibiotics. Hence, careful peak effect and recovery from the paralysis. While intermediate monitoring should be planned to prevent complications due dose (0.2 mg/kg) roxatidine significantly antagonized to drug interactions with neuromuscular blockers. Also, pipecuronium-induced paralysis (increased in ID 50 value) and decrease in dose of pipecuronium or other non-depolarizing increased the time required for the onset of peak effect, agent is suggested when H 2 antagonists are used as without affecting the recovery time.
preanaesthetic agents. Hence, these drugs should be Roxatidine acetate produced biphasic effects on the administered with careful monitoring in such patients as vital isolated rat phrenic nerve hemidiaphragm preparation. [20] This functions may be affected. effect is similar to that produced by depolarising blockers, References i.e., dual action with initial potentiation of the basal contractile twitch responses (agonistic action) at lower doses followed acetate. [11, 20] Also, increase in the time required for onset and with significant increase in the time required to produce peak vivo. [11] McCarthy G, Mirakhur RK, Elliott P, Wright J. Effects of H -receptor antagonist 2 pretreatment on vecuconium-and atracurium induced neuromuscular block.
paralysis as well as recovery from the paralysis. Enhancement of d-tubocurarine, [11] pancuronium [21] and vecuronium [20] induced paralysis by roxatidine acetate has been reported. The mechanism of potentiation of pipecuronium-induced paralysis by roxatidine acetate could be due to decrease in calcium influx at presynaptic site.
[11] However, Choksi [20] reported that in isolated rat phrenic nerve hemidiaphragm preparation the neuromuscular blockade produced by higher concentration of roxatidine acetate was not reversed by calcium chloride, neostigmine and potassium chloride suggesting a depolarising type of block of roxatidine acetate. It is reported that prior administration of a depolarising blocker antagonized or had no effect on the paralysis produced by non-depolarising neuromuscular blocker. ) .
